1-[4-(4-Methylphenyl)piperidin-1-yl]propan-1-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-[4-(4-Methylphenyl)piperidin-1-yl]propan-1-one
• 英文别名: 1-[4-(4-methylphenyl)piperidin-1-yl]propan-1-one
• 化学式: C₁₅H₂₁NO
• 分子量: 231.33
• InChiKey: FWKCZYPLRUNCFX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• SUBSTITUTED PICOLINAMIDE KINASE INHIBITORS
  申请人：Portola Pharmaceuticals, Inc.

  公开号：US20140113931A1

  公开（公告）日：2014-04-24

  Provided are picolinamide compounds for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibiting Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.

  提供了用于抑制Syk激酶的吡啶甲酰胺化合物，制备这种化合物所使用的中间体，制备这种化合物的方法，制备药物组成物的方法，抑制Syk激酶活性的方法以及治疗至少部分通过Syk激酶活性介导的疾病的方法。
• BICYCLIC OXA-LACTAM KINASE INHIBITORS
  申请人：PORTOLA PHARMACEUTICALS, INC.

  公开号：US20150252056A1

  公开（公告）日：2015-09-10

  Provided are bicyclic oxa-lactam compounds for inhibition of JAK/Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibiting JAK/Syk kinase activity, and methods for treating conditions mediated at least in part by JAK/Syk kinase activity.

  提供了双环氧内酰胺化合物，用于抑制JAK/Syk激酶，用于制备这种化合物的中间体，其制备方法，制备这种化合物的制药组合物，抑制JAK/Syk激酶活性的方法，以及治疗至少部分由JAK/Syk激酶活性介导的疾病的方法。
• NICOTINAMIDES AS JAK KINASE MODULATORS
  申请人：PORTOLA PHARMACEUTICALS, INC.

  公开号：US20150353495A1

  公开（公告）日：2015-12-10

  The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

  本发明涉及式I化合物及其药学上可接受的盐、酯和前药，它们是JAK激酶抑制剂。本发明还涉及用于制备这种化合物的中间体，制备这种化合物的方法，含有这种化合物的药物组合物，抑制JAK激酶活性的方法，抑制血小板聚集的方法，以及预防或治疗至少部分由JAK激酶活性介导的多种疾病，如不良血栓形成和非霍奇金淋巴瘤的方法。
• [EN] THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF<br/>[FR] AGENTS THÉRAPEUTIQUES POUR LA DÉGRADATION DE BRAF MUTANTE
  申请人：C4 THERAPEUTICS INC

  公开号：WO2022261250A1

  公开（公告）日：2022-12-15

  The present invention provides compounds or their pharmaceutically acceptable salts and their pharmaceutical compositions that can be administered to a host such as a human in need thereof for the treatment of a disorder, such as cancer, mediated by mutant BRAF. The compounds efficiently degrade Class I, II and III mutant BRAF proteins.

  本发明提供了化合物或其药学上可接受的盐类及其药物组合物，这些化合物或其药学上可接受的盐类及其药物组合物可施用给需要的宿主（如人类），用于治疗由突变 BRAF 介导的疾病（如癌症）。这些化合物能有效降解 I、II 和 III 类突变 BRAF 蛋白。
• BICYCLIC DIHYDROPYRIDONE KINASE INHIBITORS
  申请人：Portola Pharmaceuticals, Inc.

  公开号：EP2900639B1

  公开（公告）日：2017-08-16